Jounce Therapeutics to Participate in a Fireside Chat at BTIG Virtual Biotechnology Conference 2020
August 04 2020 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
Richard Murray, Ph.D., chief executive officer and president of
Jounce Therapeutics,will participate in a fireside chat at the BTIG
Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020
at 2:00 PM ET.
A live webcast of the presentation will be available by visiting
"Events & Presentations" in the Investors and Media section of
the company's website at www.jouncetx.com. A replay of the webcast
will be archived for 30 days following the presentation.
About Jounce Therapeutics:
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy
company dedicated to transforming the treatment of cancer by
developing therapies that enable the immune system to attack tumors
and provide long-lasting benefits to patients through a
biomarker-driven approach. Jounce currently has four
development-stage programs, two of which are clinical-stage:
vopratelimab, a monoclonal antibody that binds to and activates
ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use
with Jounce’s broader pipeline. Vopratelimab is currently being
assessed in a Phase 2 clinical trial, EMERGE, and Jounce plans to
initiate an additional Phase 2 biomarker trial using TISvopra for
patient selection, SELECT, to assess vopratelimab in combination
with JTX-4014. Jounce’s IND-enabling preclinical programs include
JTX-8064, a LILRB2 receptor antagonist, and JTX-1811, a monoclonal
antibody designed to selectively deplete T regulatory cells in the
tumor microenvironment. For more information, please visit
www.jouncetx.com.
Investor Contact:
Komal JoshiJounce Therapeutics, Inc.(857)
320-2523kjoshi@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024